Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Charles M. Perou et al.|The Lancet|2014Cited by 4.7k
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month resultsRobert E. Coleman, Nigel Bundred, Richard de Boer et al.|Annals of Oncology|2012Cited by 337
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancerEugen Ruckhäberle, Manfred Kaufmann, Achim Rody et al.|Breast Cancer Research and Treatment|2007Cited by 297
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST StudyHolger Eidtmann, Robert E. Coleman, Richard de Boer et al.|Annals of Oncology|2010Cited by 280
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessOtto Metzger, Daniel G. Stover, Katharine A. Collier et al.|npj Breast Cancer|2021Cited by 37